Scientific Advisory Board


Heather Olson, MD, MS Neurologist, Boston Children's; Neurology Instructor, Harvard Medical

Heather Olson, MD, MS
Neurologist, Boston Children's; Neurology Instructor, Harvard Medical

Dr. Olson completed all of her post-graduate medical training in Boston including training in Pediatric Neurology, Epilepsy and Clinical Neurophysiology and Epilepsy Genetics.  Since joining the faculty at Boston Children’s Hospital in 2013, she works as a clinician and clinical researcher with a focus on Neurogenetic disorders and Epilepsy. Olsen has recently opened a FOXG1 clinic at Children’s Hospital Boston, and is assisting with the creation of a sister clinic at Children’s Hospital Stanford. She is also director of the CDKL5 Center of Excellence, a combined clinical and research program.

Dr. Olson completed all of her post-graduate medical training in Boston including training in Pediatric Neurology, Epilepsy and Clinical Neurophysiology and Epilepsy Genetics.  Since joining the faculty at Boston Children’s Hospital in 2013, she works as a clinician and clinical researcher with a focus on Neurogenetic disorders and Epilepsy.

Olsen has recently opened a FOXG1 clinic at Children’s Hospital Boston, and is assisting with the creation of a sister clinic at Children’s Hospital Stanford. She is also director of the CDKL5 Center of Excellence, a combined clinical and research program.

Orrin Devinsky MDNeurosurgeon, NYU Langone, Chief of Service, NYU Epilepsy

Orrin Devinsky
MDNeurosurgeon, NYU Langone, Chief of Service, NYU Epilepsy

Dr. Orrin Devinsky is a leading neurologist and neurosurgeon at NYU Langone and professor of neurology, neurosurgery, and psychiatry at the New York University School of Medicine. His epilepsy research includes sudden unexpected death in epilepsy (SUDEP), cannabinoids, phenome-genome correlations, autism, neural markers and imaging, therapeutic electrical stimulation, quality-of-life, cognitive and behavioral issues, and surgical therapy. Devinsky received his medical degree from Harvard Medical School, founded Finding A Cure for Epilepsy and Seizures (FACES) and co-founded epilepsy.com. Devinsky was a lead neurologist in CBD clinical trials for the treatment of epilepsy.

Dr. Orrin Devinsky is a leading neurologist and neurosurgeon at NYU Langone and professor of neurology, neurosurgery, and psychiatry at the New York University School of Medicine. His epilepsy research includes sudden unexpected death in epilepsy (SUDEP), cannabinoids, phenome-genome correlations, autism, neural markers and imaging, therapeutic electrical stimulation, quality-of-life, cognitive and behavioral issues, and surgical therapy.

Devinsky received his medical degree from Harvard Medical School, founded Finding A Cure for Epilepsy and Seizures (FACES) and co-founded epilepsy.com. Devinsky was a lead neurologist in CBD clinical trials for the treatment of epilepsy.

Gordon Fishell, PhD Scientist, Broad Institute; Professor, Harvard Medical School

Gordon Fishell, PhD
Scientist, Broad Institute; Professor, Harvard Medical School

Dr Fishell received his PhD in neurobiology from the University of Toronto-Neurobiology Research Group, and works on the study of inhibitory interneurons in the brain and other deep, foundational brain sciences. Fishell recently joined the Broad Institute, where the CRISPR cut-and-paste gene editing method was discovered, and is Professor at Harvard Medical School. He was formerly a Julius Raynes Professor of Neuroscience and Associate Director of the NYU Neuroscience Institute. Fishell’s research interests are focused on the Molecular Genetics of Regional Patterning in the Mammalian Telencephalon, and Molecular Control of Neural Stem Cell Proliferation and Specification. He has published over 100 original papers, and five books.

Dr Fishell received his PhD in neurobiology from the University of Toronto-Neurobiology Research Group, and works on the study of inhibitory interneurons in the brain and other deep, foundational brain sciences.

Fishell recently joined the Broad Institute, where the CRISPR cut-and-paste gene editing method was discovered, and is Professor at Harvard Medical School. He was formerly a Julius Raynes Professor of Neuroscience and Associate Director of the NYU Neuroscience Institute. Fishell’s research interests are focused on the Molecular Genetics of Regional Patterning in the Mammalian Telencephalon, and Molecular Control of Neural Stem Cell Proliferation and Specification. He has published over 100 original papers, and five books.

Steven Gray, PhD Scientist, Gene Therapy Center at UNC School of Medicine

Steven Gray, PhD
Scientist, Gene Therapy Center at UNC School of Medicine

Dr. Gray is a leading expert in gene therapy for brain related diseases. His research focuses on developing virus systems that can be implanted with the corrected genes of various genetic disorders and introduced to the nervous system to repair mutated genes. Gray has also begun preclinical animal model studies using these virus systems to treat neurological diseases, and is currently involved in the first human trial with AveXis Biotech to cure the MECP2 mutation (RETT’s Syndrome).

Dr. Gray is a leading expert in gene therapy for brain related diseases. His research focuses on developing virus systems that can be implanted with the corrected genes of various genetic disorders and introduced to the nervous system to repair mutated genes.

Gray has also begun preclinical animal model studies using these virus systems to treat neurological diseases, and is currently involved in the first human trial with AveXis Biotech to cure the MECP2 mutation (RETT’s Syndrome).

Kiran Reddy, MD CEO, Praxis Precision Medicines, Former Partner, Clarus Ventures

Kiran Reddy, MD
CEO, Praxis Precision Medicines, Former Partner, Clarus Ventures

Dr. Reddy is President & CEO of Praxis Precision Medicines, a Cambridge, Massachusetts based biotechnology company operating in stealth mode. Formerly, he was a Venture Partner at Clarus where he focused on new company formation and at Biogen as part of the Corporate Strategy leadership team. Reddy was part of the founding team and interim Chief Business Officer for SAGE Therapeutics through its IPO, and co-inventor of SAGE-547 the Phase 3 program for the rare epilepsy disorder refractory status epilepticus. He was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Reddy holds MD and MBA degrees from Georgetown University, and is a board certified neurologist; he has authored several peer-reviewed scientific papers in the field of neuroimmunology and neurodegenerative diseases.

Dr. Reddy is President & CEO of Praxis Precision Medicines, a Cambridge, Massachusetts based biotechnology company operating in stealth mode. Formerly, he was a Venture Partner at Clarus where he focused on new company formation and at Biogen as part of the Corporate Strategy leadership team.

Reddy was part of the founding team and interim Chief Business Officer for SAGE Therapeutics through its IPO, and co-inventor of SAGE-547 the Phase 3 program for the rare epilepsy disorder refractory status epilepticus. He was part of the team that launched Foundation Medicine, and he has served as a Board Observer for Alnara pharmaceuticals, Rhythm pharmaceuticals, and PanOptica pharmaceuticals. Reddy holds MD and MBA degrees from Georgetown University, and is a board certified neurologist; he has authored several peer-reviewed scientific papers in the field of neuroimmunology and neurodegenerative diseases.

Ingrid Scheffer, PhD, Pediatric Neurologist, Physician Scientist, University of Melbourne & Florey Institute

Ingrid Scheffer, PhD, Pediatric Neurologist, Physician Scientist, University of Melbourne & Florey Institute

Dr. Scheffer is Chair of Paediatric Neurology Research at The University of Melbourne and Senior Principal Research Fellow at the Florey Institute of Neuroscience and Mental Health. Professor Scheffer is a founding fellow of the Australian Academy of Health and Medical Sciences and currently its Vice-President. Scheffer is credited with finding the first gene implicated in epilepsy. She has also described and classified novel epileptic syndromes such as Epilepsy limited to Females with Mental Retardation. Scheffer has worked to characterise new epilepsy syndromes, from infancy to adulthood, which have permitted appropriate treatment and diagnosis, such as Dravet Syndrome.  She has considerably expanded our understanding of the spectrum of epilepsies associated with glucose transporter deficiency; this body of work carries major treatment implications as this disorder responds to the ketogenic diet.

Dr. Scheffer is Chair of Paediatric Neurology Research at The University of Melbourne and Senior Principal Research Fellow at the Florey Institute of Neuroscience and Mental Health. Professor Scheffer is a founding fellow of the Australian Academy of Health and Medical Sciences and currently its Vice-President. Scheffer is credited with finding the first gene implicated in epilepsy. She has also described and classified novel epileptic syndromes such as Epilepsy limited to Females with Mental Retardation.

Scheffer has worked to characterise new epilepsy syndromes, from infancy to adulthood, which have permitted appropriate treatment and diagnosis, such as Dravet Syndrome.  She has considerably expanded our understanding of the spectrum of epilepsies associated with glucose transporter deficiency; this body of work carries major treatment implications as this disorder responds to the ketogenic diet.

Elli Brimble, MSc, MS, CGC Geneticist, Lucille Packard Children’s Hospital at Stanford

Elli Brimble, MSc, MS, CGC
Geneticist, Lucille Packard Children’s Hospital at Stanford

Brimble serves as FOXG1 Research’s Scientific Advisory Board Liaison to facilitate communication with research communities. She is a genetic counselor in Child Neurology at Stanford Children’s Health, where she is working to develop a FOXG1 multidisciplinary clinic. Brimble completed her undergraduate training in genetics at Western University in Ontario, and Masters degrees in molecular genetics and genetic counseling at the University of Toronto and Boston University, respectively. Brimble’s primary clinical and research interests are to improve understanding of genetic mechanisms that contribute to epilepsy, and to develop protocols that ensure comprehensive and consistent evaluations for genetic epileptic encephalopathies.

Brimble serves as FOXG1 Research’s Scientific Advisory Board Liaison to facilitate communication with research communities. She is a genetic counselor in Child Neurology at Stanford Children’s Health, where she is working to develop a FOXG1 multidisciplinary clinic. Brimble completed her undergraduate training in genetics at Western University in Ontario, and Masters degrees in molecular genetics and genetic counseling at the University of Toronto and Boston University, respectively.

Brimble’s primary clinical and research interests are to improve understanding of genetic mechanisms that contribute to epilepsy, and to develop protocols that ensure comprehensive and consistent evaluations for genetic epileptic encephalopathies.

Neil Kumar, PhD CEO, BridgeBio Pharma, Former Principal, Third Rock Ventures

Neil Kumar, PhD
CEO, BridgeBio Pharma, Former Principal, Third Rock Ventures

Dr Kumar is CEO of biotech company BridgeBio, focused on the development of new therapies for rare genetic disorders. Previously, he was a principal at Third Rock Ventures, where he supported and managed various biotech portfolio companies, in addition to focusing on new company formation and due diligence. He also held the role of Vice President, Business Development and Operations for MyoKardia. Kumar is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds BS and MS degrees in chemical engineering from Stanford University, and his PhD in chemical engineering from the Massachusetts Institute of Technology.

Dr Kumar is CEO of biotech company BridgeBio, focused on the development of new therapies for rare genetic disorders. Previously, he was a principal at Third Rock Ventures, where he supported and managed various biotech portfolio companies, in addition to focusing on new company formation and due diligence. He also held the role of Vice President, Business Development and Operations for MyoKardia.

Kumar is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds BS and MS degrees in chemical engineering from Stanford University, and his PhD in chemical engineering from the Massachusetts Institute of Technology.

Xilma Ortiz-Gonzalez, MD, PhD Pediatric Neurologist, CHOP, Neurology Instructor, University of Pennsylva

Xilma Ortiz-Gonzalez, MD, PhD
Pediatric Neurologist, CHOP, Neurology Instructor, University of Pennsylva

Dr. Ortiz-Gonzalez is a pediatric neurologist at Children’s Hospital of Philadelphia (CHOP) where she sees patients with FOXG1 Syndrome as well as those with numerous other genetic mutations. Ortiz-Gonzalez’s research focus is on mitochondrial disorders often present in childhood with systemic disease, including cardiac, skeletal muscle, visual and neurologic symptoms. She is interested in using iPSC technology to generate in vitro disease models to understand cardiac and neural phenotypes from patients affected with mitochondrial diseases and has published numerous articles on the topic.

Dr. Ortiz-Gonzalez is a pediatric neurologist at Children’s Hospital of Philadelphia (CHOP) where she sees patients with FOXG1 Syndrome as well as those with numerous other genetic mutations.

Ortiz-Gonzalez’s research focus is on mitochondrial disorders often present in childhood with systemic disease, including cardiac, skeletal muscle, visual and neurologic symptoms. She is interested in using iPSC technology to generate in vitro disease models to understand cardiac and neural phenotypes from patients affected with mitochondrial diseases and has published numerous articles on the topic.

Mary Jones, MD Pediatrician, Head, Katie's RETT Clinic at UCSF Oakland

Mary Jones, MD
Pediatrician, Head, Katie's RETT Clinic at UCSF Oakland

Dr. Mary Jones spent 31 years as a pediatrician as part of the East Bay Pediatrics family in California. When one of her patient’s - Katie - was diagnosed with RETT Syndrome, she became dedicated to understanding the disease in order to provide the specialized care needed. She decided to leave general pediatric practice and establish Katie's Clinic for Rett Syndrome at Children's Hospital and Research Center Oakland. Katie's Clinic offers both clinical and emotional support for individuals with Rett Syndrome and their families. Dr Jones’ Katie’s Clinic is part of the NIH funded Natural History Study for RETT, CDLK5 and FOXG1. She is zealously working to extend clinics such as hers and create greater focus on the study of rare diseases.

Dr. Mary Jones spent 31 years as a pediatrician as part of the East Bay Pediatrics family in California. When one of her patient’s - Katie - was diagnosed with RETT Syndrome, she became dedicated to understanding the disease in order to provide the specialized care needed. She decided to leave general pediatric practice and establish Katie's Clinic for Rett Syndrome at Children's Hospital and Research Center Oakland. Katie's Clinic offers both clinical and emotional support for individuals with Rett Syndrome and their families.

Dr Jones’ Katie’s Clinic is part of the NIH funded Natural History Study for RETT, CDLK5 and FOXG1. She is zealously working to extend clinics such as hers and create greater focus on the study of rare diseases.

Sookyong Koh, MD, PhD Pediatric Neurologist, Children’s Healthcare of Atlanta; Professor, Emory University School of Medicine

Sookyong Koh, MD, PhD
Pediatric Neurologist, Children’s Healthcare of Atlanta; Professor, Emory University School of Medicine

Dr. Koh is a pediatric neurologist at Children’s Healthcare of Atlanta and Associate Professor in the division of Neurology and Pediatrics at Emory School of Medicine. She was previously an instructor within the Department of Neurology at Harvard Medical School, and an Assistant in Neurology at Children's Hospital in Boston. As a scientist, Koh has proposed "two-hit hypothesis of epileptogenesis” to provide a useful conceptual framework for understanding the contribution of early life events to the future development of epilepsy. Koh has conducted research to test anti-inflammatory drugs already in clinical use or ready to undergo clinical trial in a clinically relevant animal model in order to determine whether early anti-inflammatory therapy can alter disease progression and the devastating long-term neurological outcome of prolonged early life convulsions.

Dr. Koh is a pediatric neurologist at Children’s Healthcare of Atlanta and Associate Professor in the division of Neurology and Pediatrics at Emory School of Medicine. She was previously an instructor within the Department of Neurology at Harvard Medical School, and an Assistant in Neurology at Children's Hospital in Boston.

As a scientist, Koh has proposed "two-hit hypothesis of epileptogenesis” to provide a useful conceptual framework for understanding the contribution of early life events to the future development of epilepsy. Koh has conducted research to test anti-inflammatory drugs already in clinical use or ready to undergo clinical trial in a clinically relevant animal model in order to determine whether early anti-inflammatory therapy can alter disease progression and the devastating long-term neurological outcome of prolonged early life convulsions.

Robin Kleiman, Ph.D Senior Director, Biogen Research Associate, Boston Children’s Hospita

Robin Kleiman, Ph.D Senior Director, Biogen Research Associate, Boston Children’s Hospita

Dr. Kleiman has contributed to the discovery and development of multiple novel clinical candidates and has worked at companies that span the big pharma, start-up and biotech industries. She was one of several founding members of the Pfizer Neuroscience Phosphodiesterase platform team that produced multiple clinical candidate molecules, 3 first-in-human clinical trials for distinct and completely novel mechanisms followed by 2 proof-of-concept clinical trials. Kleiman joined the Translational Neuroscience Center leadership team and faculty at Boston’s Children’s Hospital in August of 2013 as the Head of Preclinical Research to provide drug discovery expertise to the members of the TNC community, develop a robust portfolio of translational research projects and foster more in-depth collaboration with industry and disease-based foundations to develop novel therapies to improve the lives of pediatric and adolescent patients.  

Dr. Kleiman has contributed to the discovery and development of multiple novel clinical candidates and has worked at companies that span the big pharma, start-up and biotech industries. She was one of several founding members of the Pfizer Neuroscience Phosphodiesterase platform team that produced multiple clinical candidate molecules, 3 first-in-human clinical trials for distinct and completely novel mechanisms followed by 2 proof-of-concept clinical trials.

Kleiman joined the Translational Neuroscience Center leadership team and faculty at Boston’s Children’s Hospital in August of 2013 as the Head of Preclinical Research to provide drug discovery expertise to the members of the TNC community, develop a robust portfolio of translational research projects and foster more in-depth collaboration with industry and disease-based foundations to develop novel therapies to improve the lives of pediatric and adolescent patients.  

Aris Economides, PhD Vice President of Research, Regeneron Pharmaceuticals 

Aris Economides, PhD
Vice President of Research, Regeneron Pharmaceuticals 

Dr Economides leads Genetic Research at Regeneron which includes Genome Engineering Technologies and Skeletal Diseases TFA. He is a co-inventor of the Cytokine Trap technology that led to the development of the IL-1 trap, a currently approved biologic drug (ARCALYST™). He is also a co-inventor of the VelociGene® technology, that has led to the development of VelocImmune®, a method for the generation of all-human antibodies in mice.  More recently, Economides has been spearheading the development of new methods for the generation of transgenic mice using BAC as transgene vectors, and has also pioneered a new method for generating conditional alleles.

Dr Economides leads Genetic Research at Regeneron which includes Genome Engineering Technologies and Skeletal Diseases TFA. He is a co-inventor of the Cytokine Trap technology that led to the development of the IL-1 trap, a currently approved biologic drug (ARCALYST™). He is also a co-inventor of the VelociGene® technology, that has led to the development of VelocImmune®, a method for the generation of all-human antibodies in mice. 

More recently, Economides has been spearheading the development of new methods for the generation of transgenic mice using BAC as transgene vectors, and has also pioneered a new method for generating conditional alleles.